{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T22:28:40Z","timestamp":1783722520620,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.phrs.2017.04.025","type":"journal-article","created":{"date-parts":[[2017,4,26]],"date-time":"2017-04-26T09:02:21Z","timestamp":1493197341000},"page":"184-193","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Suppression of ABCG2 mediated MDR in vitro and in vivo by a novel inhibitor of ABCG2 drug transport"],"prefix":"10.1016","volume":"121","author":[{"given":"Atish","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian-Wen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagaraju","family":"Anreddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"De-Shen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamlesh","family":"Sodani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanket","family":"Gadhia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishil","family":"Kathawala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Hua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changmei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe-Sheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2017.04.025_bib0005","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1101\/SQB.1994.059.01.078","article-title":"Exploiting multidrug resistance to treat cancer","volume":"59","author":"Gottesman","year":"1994","journal-title":"Cold Spring Harb Symp. Quant. Biol."},{"key":"10.1016\/j.phrs.2017.04.025_bib0010","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1146\/annurev.med.53.082901.103929","article-title":"Mechanisms of cancer drug resistance","volume":"53","author":"Gottesman","year":"2002","journal-title":"Annu. Rev. Med."},{"issue":"6","key":"10.1016\/j.phrs.2017.04.025_bib0015","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1016\/0959-8049(96)00111-6","article-title":"Pharmacological considerations in the modulation of multidrug resistance","volume":"32A","author":"Fisher","year":"1996","journal-title":"Eur. J. Cancer"},{"issue":"3-4","key":"10.1016\/j.phrs.2017.04.025_bib0020","first-page":"57","article-title":"Resorption and calcification of chemically modified collagen\/hyaluronan hybrid membranes","volume":"30","author":"Bakos","year":"2000","journal-title":"Polim. Med."},{"issue":"26","key":"10.1016\/j.phrs.2017.04.025_bib0025","doi-asserted-by":"crossref","first-page":"15665","DOI":"10.1073\/pnas.95.26.15665","article-title":"A multidrug resistance transporter from human MCF-7 breast cancer cells","volume":"95","author":"Doyle","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"1","key":"10.1016\/j.phrs.2017.04.025_bib0030","first-page":"8","article-title":"Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes","volume":"59","author":"Miyake","year":"1999","journal-title":"Cancer Res."},{"issue":"18","key":"10.1016\/j.phrs.2017.04.025_bib0035","first-page":"4559","article-title":"Overexpression of the BCRP\/MXR\/ABCP gene in a topotecan-selected ovarian tumor cell line","volume":"59","author":"Maliepaard","year":"1999","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.phrs.2017.04.025_bib0040","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/sj.bjc.6601370","article-title":"Mutations at amino-acid 482 in the ABCG2 gene affect substrate and antagonist specificity","volume":"89","author":"Robey","year":"2003","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2017.04.025_bib0045","unstructured":"J.T. Zhang, Biochemistry and pharmacology of the human multidrug resistance gene product, ABCG2, Zhong Nan Da Xue Xue Bao Yi Xue Ban 32(4)(2007)531-41."},{"issue":"8","key":"10.1016\/j.phrs.2017.04.025_bib0050","first-page":"3052","article-title":"Expression and functional analyses of breast cancer resistance protein in lung cancer","volume":"9","author":"Kawabata","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.phrs.2017.04.025_bib0055","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1177\/1087057105284576","article-title":"A high-throughput cell-based assay for inhibitors of ABCG2 activity","volume":"11","author":"Henrich","year":"2006","journal-title":"J. Biomol. Screen"},{"issue":"19","key":"10.1016\/j.phrs.2017.04.025_bib0060","doi-asserted-by":"crossref","first-page":"7905","DOI":"10.1158\/0008-5472.CAN-08-0499","article-title":"Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2","volume":"68","author":"Dai","year":"2008","journal-title":"Cancer Res."},{"issue":"12","key":"10.1016\/j.phrs.2017.04.025_bib0065","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.bcp.2012.02.028","article-title":"GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse ABCG2- and ABCB1-mediated drug resistance","volume":"83","author":"Sodani","year":"2012","journal-title":"Biochem. Pharmacol."},{"issue":"12 Pt 1","key":"10.1016\/j.phrs.2017.04.025_bib0070","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1158\/1535-7163.MCT-07-0352","article-title":"New inhibitors of ABCG2 identified by high-throughput screening","volume":"6","author":"Henrich","year":"2007","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.phrs.2017.04.025_bib0075","first-page":"105","article-title":"Reversal of breast cancer resistance protein-mediated drug resistance by estrogen antagonists and agonists","volume":"2","author":"Sugimoto","year":"2003","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.phrs.2017.04.025_bib0080","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/ijc.11528","article-title":"Reversal of breast cancer resistance protein (BCRP\/ABCG2)-mediated drug resistance by novobiocin, a coumermycin antibiotic","volume":"108","author":"Shiozawa","year":"2004","journal-title":"Int. J. Cancer"},{"issue":"1\u20132","key":"10.1016\/j.phrs.2017.04.025_bib0085","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.drup.2005.02.002","article-title":"Tyrosine kinase inhibitor resistance in cancer: role of ABC multidrug transporters","volume":"8","author":"Ozvegy-Laczka","year":"2005","journal-title":"Drug Resistance Updates"},{"issue":"11","key":"10.1016\/j.phrs.2017.04.025_bib0090","first-page":"2964","article-title":"Discovery and characterization of OC144-093, a novel inhibitor of P-glycoprotein-mediated multidrug resistance","volume":"60","author":"Newman","year":"2000","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.phrs.2017.04.025_bib0095","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1158\/0008-5472.CAN-08-1856","article-title":"Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3","volume":"69","author":"Michaelis","year":"2009","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.phrs.2017.04.025_bib0100","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.canlet.2012.10.001","article-title":"Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-, ABCG2-, and ABCC10-multidrug resistance xenograft models","volume":"328","author":"Tiwari","year":"2013","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.phrs.2017.04.025_bib0105","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1158\/1535-7163.MCT-10-0874","article-title":"Novel acrylonitrile derivatives, YHO-13177 and YHO-13351, reverse BCRP\/ABCG2-mediated drug resistance in vitro and in vivo","volume":"10","author":"Yamazaki","year":"2011","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.phrs.2017.04.025_bib0110","first-page":"145","article-title":"Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr\/BCrp\/ABCP1), in flavopiridol-resistant human breast cancer cells","volume":"7","author":"Robey","year":"2001","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.phrs.2017.04.025_bib0115","first-page":"4186","article-title":"Phase I trial of XR9576 in healthy volunteers demonstrates modulation of P-glycoprotein in CD56+ lymphocytes after oral and intravenous administration","volume":"6","author":"Stewart","year":"2000","journal-title":"Clin. Cancer Res."},{"issue":"16","key":"10.1016\/j.phrs.2017.04.025_bib0120","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1158\/0008-5472.CAN-12-0743","article-title":"HG-829 is a potent noncompetitive inhibitor of the ATP-binding cassette multidrug resistance transporter ABCB1","volume":"72","author":"Caceres","year":"2012","journal-title":"Cancer Res."},{"issue":"24","key":"10.1016\/j.phrs.2017.04.025_bib0125","first-page":"5850","article-title":"Reversal of a novel multidrug resistance mechanism in human colon carcinoma cells by fumitremorgin C","volume":"58","author":"Rabindran","year":"1998","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.phrs.2017.04.025_bib0130","first-page":"417","article-title":"Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C","volume":"1","author":"Allen","year":"2002","journal-title":"Mol. Cancer Ther."},{"issue":"6859","key":"10.1016\/j.phrs.2017.04.025_bib0135","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/35102167","article-title":"Stem cells, cancer, and cancer stem cells","volume":"414","author":"Reya","year":"2001","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.phrs.2017.04.025_bib0140","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1038\/nrc1590","article-title":"Tumour stem cells and drug resistance","volume":"5","author":"Dean","year":"2005","journal-title":"Nat. Rev. Cancer"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661817300622?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661817300622?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,2]],"date-time":"2018-09-02T10:21:50Z","timestamp":1535883710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661817300622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":28,"alternative-id":["S1043661817300622"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2017.04.025","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Suppression of ABCG2 mediated MDR in vitro and in vivo by a novel inhibitor of ABCG2 drug transport","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2017.04.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}